Radicle Science is an AI-driven, healthtech B-corp proving the effects of health and wellness products. Our crowdsourced, virtual, direct-to-consumer clinical trial approach is 10x cheaper and faster than traditional research. This enables non-pharmaceuticals to be validated at scale for the first time in history, transforming them into precision health solutions.

Tech Brief

Just like Ford Motors did not create a faster horse, Radicle Science did not create a better clinical trial. Instead, Radicle Science has created a fundamentally new and different method for evidence-generation on non-prescription products by synthesizing knowledge from clinical trials, big data, virtualization, behavioral science, digital health, social media, and direct-to-consumer business models. In essence, we have democratized clinical evidence generation. We believe this much-needed clinical data can be used to transform non-pharmaceutical products into democratized precision health solutions.

Problem Tech Solves

We enable the filling of the glaring gap in clinical data for consumer health and wellness products that don’t require FDA approval. There are nearly $60B of non-prescription nutraceuticals sold in the U.S. each year. The vast majority has not been clinically studied due to the prohibitive cost and slow turnaround time of traditional trials; these non-prescription products do not have the patent/monopoly model of pharmaceuticals to justify such large investments in trials. Yet more than 50% of the small molecule drugs ever approved by the FDA were first discovered in plants! Thus, nutraceuticals hold immense potential for human health - if only we had objective knowledge on their effectiveness, safety, dosage, and side effects. Given their democratized nature, nutraceuticals can be affordable, accessible interventions for all future generations. Just as importantly, Radicle brings much needed equity into medical research. Our large-scale, virtual, D2C trials involve more women, minorities, and rural populations than traditionally represented in clinical research. The unprecedented scale and reach of our intentionally diverse clinical trials finally enables inclusion of broad ethnicities, genders, and age groups, which all moves us closer to personalized medicine. As we enable objective data generation at scale, everyone benefits from being able to make history’s first evidence-based decisions on non-prescription products. This includes not only consumers and providers, but brands, manufacturers, retailers and distributors to even insurers and healthcare systems.


Since launching in the summer of 2021, Radicle has already completed dozens of randomized controlled trials involving more than 15,000 Americans. The Radicle ACES study was history’s largest human trial on CBD, with nearly 3,000 participants. Preliminary results are covered by MedScape. Several manuscripts are currently under review by peer-reviewed journals. Radicle is currently on track to have completed RCTs on more than 35,000 Americans by the end of 2022.